<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Longevity Review — February 2026</title>
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Hanken+Grotesk:wght@400;500;600&display=swap" rel="stylesheet">
  <style>
    @font-face { font-family: 'Copernicus Trial'; src: url('fonts/CopernicusTrial-Book.ttf') format('truetype'); font-weight: 400; }
    @font-face { font-family: 'Copernicus Trial'; src: url('fonts/CopernicusTrial-Medium.ttf') format('truetype'); font-weight: 500; }
    *, *::before, *::after { margin: 0; padding: 0; box-sizing: border-box; }
    :root {
      --text-primary: #111111; --text-secondary: #44403C; --text-tertiary: #78716C;
      --bg-primary: #F9F9F9; --bg-secondary: #FDFDFD; --bg-tertiary: #F7F6F4;
      --bg-hover-darker: #ECEAE7; --line-subtle: #E8E5E1;
      --chart-primary: #2A8F87; --highlight-info: #E3EBF5;
      --serif: 'Copernicus Trial', Georgia, serif; --sans: 'Hanken Grotesk', -apple-system, sans-serif;
      --shadow-card: 0 4px 8px rgba(0,0,0,0.04), 0 2px 4px rgba(0,0,0,0.06);
      --shadow-card-hover: 0 8px 16px rgba(0,0,0,0.06), 0 4px 8px rgba(0,0,0,0.04);
      --radius: 24px;
    }
    html { font-size: 16px; } body { font-family: var(--sans); background: var(--bg-primary); color: var(--text-primary); line-height: 1.65; }
    .nav-bar { display: flex; justify-content: center; background: var(--bg-secondary); font-size: 0.8rem; font-weight: 500; }
    .nav-bar a { text-decoration: none; color: var(--text-tertiary); padding: 0.7rem 1.5rem; margin: 4px 0; border-radius: 999px; transition: all 0.2s; }
    .nav-bar a.active { color: var(--text-primary); background: #ECEAE7; }
    .sector-tabs { display: flex; justify-content: center; gap: 0.5rem; padding: 1rem 1.5rem; background: var(--bg-secondary); flex-wrap: wrap; }
    .sector-tab { font-size: 0.8rem; font-weight: 500; text-decoration: none; padding: 0.5em 1em; border-radius: 999px; color: var(--text-secondary); background: var(--bg-secondary); }
    .sector-tab.active { background: #ECEAE7; color: var(--text-primary); }
    .masthead { background: transparent; position: relative; }
    .masthead-inner { max-width: 900px; margin: 0 auto; padding: 2.5rem 1.5rem 2rem; text-align: center; }
    .masthead .overline { font-size: 0.7rem; font-weight: 500; color: var(--text-tertiary); margin-bottom: 0.75rem; }
    .masthead h1 { font-family: var(--serif); font-size: clamp(2rem, 5vw, 3rem); font-weight: 400; margin-bottom: 0.5rem; }
    .masthead .edition-date { font-size: 0.95rem; font-weight: 500; color: var(--text-secondary); }
    .masthead .edition-sub { font-size: 0.8rem; color: var(--text-tertiary); }
    .divider-bar { width: 60px; height: 3px; background: var(--text-primary); margin: 1rem auto 0; }
    .lang-toggle { position: absolute; top: 0.75rem; right: 1rem; font-size: 0.65rem; font-weight: 500; }
    .lang-toggle a { text-decoration: none; color: var(--text-tertiary); } .lang-toggle a.active { color: var(--text-primary); }
    .container { max-width: 900px; margin: 0 auto; padding: 2rem 1.5rem 4rem; }
    .section { margin-bottom: 3rem; }
    .section-header { margin-bottom: 1.5rem; }
    .section-title { font-family: var(--serif); font-size: 1.35rem; font-weight: 500; color: var(--text-secondary); }
    .cards { display: grid; gap: 1rem; }
    .card { background: var(--bg-secondary); border-radius: var(--radius); padding: 1.25rem 1.5rem; box-shadow: var(--shadow-card); transition: all 0.2s; }
    .card:hover { box-shadow: var(--shadow-card-hover); transform: translateY(-1px); }
    .card-headline { font-family: var(--serif); font-size: 1.25rem; font-weight: 500; margin-bottom: 0.4rem; }
    .card-body { font-size: 1rem; color: var(--text-secondary); line-height: 1.6; }
    .card-tag { display: inline-block; font-size: 0.65rem; font-weight: 600; padding: 0.2em 0.6em; border-radius: 999px; margin-bottom: 0.6rem; background: var(--bg-tertiary); color: var(--text-secondary); }
    .stat-grid { display: grid; grid-template-columns: repeat(4, 1fr); gap: 1rem; margin-bottom: 2rem; }
    .stat-card { background: var(--bg-secondary); border-radius: var(--radius); padding: 1.25rem; text-align: center; box-shadow: var(--shadow-card); }
    .stat-value { font-family: var(--serif); font-size: 1.75rem; font-weight: 500; color: var(--chart-primary); }
    .stat-label { font-size: 0.7rem; font-weight: 500; color: var(--text-tertiary); margin-top: 0.35rem; }
    .highlight-box { background: var(--highlight-info); border-radius: var(--radius); padding: 1.5rem; margin-bottom: 1.5rem; }
    .highlight-title { font-family: var(--serif); font-weight: 500; font-size: 1.1rem; margin-bottom: 0.75rem; }
    .highlight-box p { font-size: 1rem; color: var(--text-secondary); line-height: 1.6; }
    .bottom-line { background: var(--bg-tertiary); border-radius: var(--radius); padding: 2rem; }
    .bottom-line p { font-size: 1rem; line-height: 1.75; color: var(--text-secondary); }
    .footer { text-align: center; padding: 2rem 1.5rem 3rem; font-size: 0.75rem; color: var(--text-tertiary); border-top: 1px solid var(--line-subtle); max-width: 900px; margin: 0 auto; }
    @media (max-width: 640px) {
      .container { width: calc(100vw - 32px); padding: 2rem 0 4rem; margin: 0 auto; }
      .card { background: transparent; box-shadow: none; border-radius: 0; padding: 0 0 1.5rem 0; border-bottom: 1px solid var(--line-subtle); }
      .card:hover { box-shadow: none; transform: none; }
      .stat-grid { grid-template-columns: repeat(2, 1fr); }
    }
  </style>
</head>
<body>
  <nav class="nav-bar">
    <a href="live.html">Live</a><a href="index.html">Daily</a><a href="vc-review.html" class="active">Review</a><a href="archive.html">Archive</a>
  </nav>
  <div class="sector-tabs">
    <a href="vc-review.html" class="sector-tab">VC</a>
    <a href="ai-review.html" class="sector-tab">AI</a>
    <a href="longevity-review.html" class="sector-tab active">Longevity</a>
    <a href="health-wellness-review.html" class="sector-tab">Health</a>
    <a href="space-review.html" class="sector-tab">Space</a>
    <a href="energy-review.html" class="sector-tab">Energy</a>
    <a href="sports-entertainment-review.html" class="sector-tab">Sports</a>
  </div>
  <header class="masthead">
    <div class="lang-toggle"><a href="longevity-review.html" class="active">EN</a><span>/</span><a href="longevity-review-ja.html">JA</a></div>
    <div class="masthead-inner">
      <div class="overline">Daily sector intelligence</div>
      <h1>Longevity review</h1>
      <div class="edition-date">February 13, 2026</div>
      <div class="edition-sub">Anti-aging · Therapeutics · Research · Biotech funding</div>
      <div class="divider-bar"></div>
    </div>
  </header>
  <main class="container">
    <section class="section">
      <div class="section-header"><h2 class="section-title">Market overview</h2></div>
      <div class="stat-grid">
        <div class="stat-card"><div class="stat-value">$42B</div><div class="stat-label">Longevity market 2026</div></div>
        <div class="stat-card"><div class="stat-value">$8.2B</div><div class="stat-label">VC funding (trailing 12mo)</div></div>
        <div class="stat-card"><div class="stat-value">47</div><div class="stat-label">Clinical trials (Phase 2+)</div></div>
        <div class="stat-card"><div class="stat-value">$257M</div><div class="stat-label">Cellares Series D</div></div>
      </div>
      <div class="highlight-box">
        <div class="highlight-title">The big story</div>
        <p><strong>Cell therapy manufacturing hits scale.</strong> Cellares' $257M raise signals the longevity sector is maturing from research to manufacturing. Meanwhile, AI is accelerating drug discovery timelines by 50%+, and Japan's aging population makes it ground zero for longevity tech deployment.</p>
      </div>
    </section>
    <section class="section">
      <div class="section-header"><h2 class="section-title">Key developments</h2></div>
      <div class="cards">
        <article class="card">
          <span class="card-tag">Cell therapy</span>
          <h3 class="card-headline">Cellares raises $257M to automate cell therapy manufacturing</h3>
          <p class="card-body">Series D led by Fidelity. Their "Cell Shuttle" platform reduces CAR-T manufacturing from weeks to days. <strong>Targeting 10x cost reduction</strong> to make cell therapies accessible beyond oncology.</p>
        </article>
        <article class="card">
          <span class="card-tag">Senolytics</span>
          <h3 class="card-headline">Unity Biotechnology Phase 2 results show promise in osteoarthritis</h3>
          <p class="card-body">Senolytic compound UBX1325 showing statistically significant improvement in knee osteoarthritis. <strong>First potential approval pathway for anti-aging drug class.</strong></p>
        </article>
        <article class="card">
          <span class="card-tag">AI drug discovery</span>
          <h3 class="card-headline">Isomorphic Labs identifies novel aging targets in 6 months</h3>
          <p class="card-body">DeepMind spinout using AlphaFold-derived methods to identify druggable aging pathways. <strong>Timeline compressed from 4 years to 6 months.</strong> Eli Lilly partnership expanded.</p>
        </article>
        <article class="card">
          <span class="card-tag">Japan</span>
          <h3 class="card-headline">Japan approves first regenerative medicine for age-related macular degeneration</h3>
          <p class="card-body">PMDA grants approval for iPSC-derived retinal cell therapy. <strong>Japan leading regulatory pathway for regenerative medicine</strong> as world's oldest population demands solutions.</p>
        </article>
        <article class="card">
          <span class="card-tag">Funding</span>
          <h3 class="card-headline">Altos Labs continues stealth hiring, rumored $500M extension</h3>
          <p class="card-body">Bezos-backed cellular reprogramming company reportedly raising additional capital. <strong>200+ scientists now employed</strong> across US, UK, and Japan campuses.</p>
        </article>
        <article class="card">
          <span class="card-tag">Research</span>
          <h3 class="card-headline">Partial reprogramming reverses aging markers in mice by 30%</h3>
          <p class="card-body">Salk Institute publishes landmark study on Yamanaka factor delivery. <strong>Epigenetic age reversal now reproducible.</strong> Human trials proposed for 2027.</p>
        </article>
      </div>
    </section>
    <section class="section">
      <div class="bottom-line">
        <div class="section-header"><h2 class="section-title">Bottom line</h2></div>
        <p>Longevity is transitioning from speculative science to clinical reality. Cell therapy manufacturing is scaling, senolytics are reaching Phase 2 endpoints, and AI is compressing drug discovery timelines dramatically. Japan's regulatory leadership and aging demographics make it the natural proving ground for these technologies. The sector is graduating from "maybe someday" to "clinical pipeline."</p>
        <p style="margin-top: 1rem; font-weight: 600;">Manufacturing scaling. Senolytics advancing. AI accelerating. Japan leading.</p>
      </div>
    </section>
  </main>
  <footer class="footer"><p>Longevity Review · Compiled by Sanbot · February 13, 2026</p></footer>
</body>
</html>
